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SUMMARY
Community-acquired Staphylococcus aureus infections are a public health concern, yet little is
known about infections that do not present to hospital. We identified community-onset S. aureus
infections via specimens submitted to a community-based pathology service. Referring doctors
confirmed eligibility and described infection site, severity and treatment. Isolates were
characterized on antibiotic resistance, PFGE, MLST/SCCmec, and Panton–Valentine leukocidin
(PVL), representing 106 community-onset infections; 34 non-multiresistant methicillin-resistant
S. aureus (nmMRSA) (resistant to <3 non-β-lactam antibiotics), 15 multiply antibiotic-resistant
MRSA (mMRSA) and 57 methicillin-sensitive S. aureus (MSSA). Most (93%) were skin and soft
tissue infections. PVL genes were carried by 42% of nmMRSA isolates [95% confidence interval
(CI) 26–61] and 15% of MSSA (95% CI 8–28). PVL was associated with infections of the trunk,
head or neck (56·4% vs. 24·3%, P=0·005) in younger patients (23 vs. 52 years, P<0·001), and
with boils or abscesses (OR 8·67, 95% CI 2·9–26·2), suggesting underlying differences in exposure
and/or pathogenesis.
Key words: Epidemiology, methicillin-resistant S. aureus (MRSA), public health emerging
infections, staphylococcal infections, Staphylococcus aureus.
INTRODUCTION
Staphylococcus aureus is a common community and
hospital pathogen in humans. It is virulent, easily
transmissible, carried for long periods, and rapidly
acquires resistance to antibiotics. Reports showed
that the number of S. aureus community-onset infec-
tions rose significantly in the late 1990s and early
2000s [1, 2], particularly in the USA where very high
attack rates are described for emergent epidemic strains
[3]. While there is some evidence that the rates have
been decreasing [4], clinicians are still having to man-
age patients with S. aureus infections arising in the
community that are both more virulent and more
resistant to antibiotics than previously encountered.
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In Australia most of the individual patient data
concerning resistance and disease burden are derived
from hospital series of S. aureus bacteraemia. While
this represents only a small fraction of all S. aureus
infections, there are an estimated 6900 episodes of
S. aureus bacteraemia annually (35/100000), associ-
ated with 25–30% mortality; at least 12% of which
are community-onset methicillin-resistant S. aureus
(MRSA) infections [5]. In a subsequent 2009
Australasian survey of invasive S. aureus disease in
hospital patients, 6% of all cases were caused by iso-
lates with a resistance profile consistent with non-
multiresistant MRSA (nmMRSA) (resistant to <3
non-β-lactam antibiotics) [6] and there have been wor-
rying reports of rapidly lethal infections in other-
wise healthy young people [7]. However, not all
community-onset MRSA strains are equally virulent
and there is marked regional variation in the distri-
bution of both virulence and resistance in Australia [8].
Although S. aureus possesses a suite of virulence
factors, most interest has been invested in one major
determinant, Panton–Valentine leukocidin (PVL), be-
cause emergent virulent community-acquired MRSA
isolates in the USA, Europe and Australia are fre-
quently PVL positive [9–11]. However, the exact role
that PVL plays in pathogenesis remains a topic of
intense controversy [12–17].
In this study we investigated prevalence and resist-
ance of S. aureus isolates identified in a cohort of
patients with community-onset S. aureus infections
who were not admitted to major hospitals. In the
first study of its kind, a stratified sampling strategy
was used that was based on private laboratory results
for infections that presented to community doctors
and small community hospitals purposefully enriched
for community MRSA infections.
METHODS
Study population
Clinical specimens submitted between April and
September 2006 to a large community-based pathol-
ogy service in Melbourne, Australia (Dorevitch
Pathology) were used to identify cases of S. aureus
infection. All S. aureus isolates were from routine
clinical specimens processed according to standard
laboratory protocols. Screening and duplicate speci-
mens were excluded, together with specimens collected
from residents of long-term care facilities, such as nur-
sing homes, and hospital patients where the specimen
was collected more than 48 h after admission or within
2 weeks post-discharge. Patient, specimen collection
and isolate details were extracted from laboratory
records (demographic information, specimen source,
isolate resistance patterns) for all cases. All eligible
MRSA cases were included. Because methicillin-
sensitive S. aureus (MSSA) cases were far more
numerous, a frequency-matched computer-generated
random subsample of MSSA cases, representing
about 5% of all MSSA, were selected for comparison.
Confirmation that the infection was community-onset,
and collection of further clinical details (infection site,
severity as judged by the treating doctor, initial and
subsequent antibiotic treatment, use of surgical drai-
nage, history of recent antibiotic use, number of return
visits) were obtained from the doctor who referred
the specimen by telephone interview. Study patients
were then allocated to one of three groups for anal-
ysis [MSSA, multi-resistant (m)MRSA, nmMRSA]
according to the resistance pattern of their initial
S. aureus isolate.
Microbiology
The following definitions were used to categorize
S. aureus infections:
MSSA: Methicillin sensitive.
nmMRSA: Non-multiresistant. Resistant to methi-
cillin but resistant to fewer than three antibiotics on
a panel of eight antibiotics: (tetracycline, erythro-
mycin, trimethoprim, ciprofloxacin, gentamicin,
rifampin, fusidic acid and mupirocin).
mMRSA: Multiresistant. Resistant to methicillin
and three or more other antibiotics on the same
panel.
Dorevitch Pathology, Melbourne, performed all
initial laboratory work on clinical isolates. S. aureus
were identified by conventional methods; catalase,
DNAse and latex tests. Any discordant results
between the DNAse and latex tests were resolved by
the tube coagulase test. Antibiotic susceptibilities
were determined by disc diffusion on Sensititre agar
according to the CDS disc method of antibiotic sensi-
tivity testing [18]: tetracycline (10 μg), erythromycin
(5 μg), ciprofloxacin (2·5 μg), gentamicin (10 μg),
rifampin (1 μg), trimethoprim (5 μg), fusidic acid
(2·5 μg), mupirocin (5 μg).
Of the 106 isolates corresponding to patients
included in the final analysis, 102were subjected tomol-
ecular characterization. Pulsed-field gel electrophoresis
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(PFGE) was performed on all isolates as described
previously [19], using a contour-clamped homogeneous
electric field (CHEF) DR III system (Bio-Rad
Laboratories Pty Ltd, USA). Chromosomal patterns
were examined visually, scanned with a Quantity
One device (Bio-Rad), and digitally analysed using
FPQuest (Bio-Rad). S. aureus strain NCTC 8325 was
used as a reference strain.
PCR for the detection of PVL determinants was
performed on all isolates as described previously
[20]. Putative MRSA multilocus sequence types were
attributed on the basis of previously characterized
MRSA PFGE types [21]. Multilocus sequence typing
(MLST) was performed according to the strategy pre-
viously described [22] on all novel MRSA PFGE types
and all PVL positive MSSA. Chromosomal DNA for
(MLST) was prepared using a DNeasy tissue kit
(Qiagen Pty Ltd, Germany). The sequences were sub-
mitted to http://www.mlst.net/ where an allelic profile
was generated and a sequence type (ST) assigned.
Clonal complex (CC) was determined using the
eBURST V3 algorithm at the same website. Clones
that diverged in only one of the seven MLST loci
were considered to belong to the same CC. Double
locus variants (DLVs) were included if the linking
single locus variant (SLV) was present in the MLST
database. Staphylococcal cassette chromosome mec
(SCCmec) typing was performed on novel MRSA
PFGE types as described previously [23].
Statistical analysis
χ2 and t tests were performed and exact 95%
confidence intervals (CIs) computed to compare
patient and infection characteristics by resistance
group and PVL status. Logistic regression was used
to estimate odds ratios (ORs) for PVL and clinically
initiated surgical drainage treatment adjusted for age
and infection type and site. Infection site categories
were collapsed into ‘axilla’, ‘head and neck’, and
‘other’ for multivariate analysis. Analysis of PVL
positivity and associations with patient and infection
characteristics was restricted to 86 nmMRSA and
MSSA cases where PVL results were available. The
mMRSA infections were excluded from this compara-
tive analysis as PVL genes had not been reported in
these strains.
Estimating the overall prevalence of MRSA among
community-onset infections had to take into account
that all MRSA were included in the study, while
only a random sample of MSSA cases was included.
We first estimated how many of the total MSSA iso-
lates from the collection period were likely to be
associated with community-onset infections by apply-
ing the MSSA eligibility fractions for the study
sample to the total MSSA isolates. This was used
to reconstruct the probable profile of S. aureus isolates
by resistance type associated with community-
onset infections through this period. The 95% CIs
for the prevalence estimates were also computed
and weighted according to the original sampling
fractions. All computations were performed with
Stata version 11 (StataCorp., USA) and SPSS version
20 (SPSS Inc., USA).
Ethical approval
The project was approved by the University of Mel-




In total, 2094 S. aureus were isolated by Dorevtich
Pathology in the 6-month study period, 11·7% were
MRSA, 6·4% mMRSA and 5·3% nmMRSA
(Fig. 1). The majority of referring doctors were gen-
eral practitioners. We achieved a high response rate
with 87% of the doctors approached agreeing to par-
ticipate in the study. A number of doctors elected to
contact their patients for permission before agreeing
to participate, although this was not a requirement.
The recruitment rate was slightly higher for those
doctors who had referred a MRSA infection, but
still approached 80% in the MSSA group. The median
time lag from specimen collection to interview was
33·5 days, ranging from 9 to 84 days. There was no
discernible difference in the demographic profile of
patients of those doctors who decided to participate
and those who did not.
The majority of mMRSA infections were re-
ported by the doctors to be associated with a hospital
admission (70%) and therefore did not meet eligibility
criteria. Although the majority of nmMRSA infec-
tions were initially thought to be community onset,
45% of patients reported recent hospital exposure.
All but 9% of MSSA cases were confirmed as
community-onset. The final number of S. aureus iso-
lates included that were confirmed to be
community-onset infections was 106; 15 mMRSA,
34 nmMRSA and 57 MSSA (Table 1).
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Patient and infection characteristics
The majority of patients presented with skin and soft
tissue infections (93%). Table 1 presents the patient
profile and infections characteristics stratified by the
different antibiotic resistance groups. Patients with
mMRSA infections were on average older and, con-
sistent with older age, were more likely to be female.
They were also more likely to have been prescribed
antibiotics in the previous 12 months.
Doctors were asked to self-rate the severity of their
patient’s infection as ‘mild’, ‘moderate’ or ‘severe’.
The proportion of infections that were rated as ‘severe’
did not differ across resistance groups. Infections were
less often reported as ‘mild’ for nmMRSA, but again
this did not approach statistical significance.
The distribution of infection site did differ between
the three resistance groups, with mMRSA infections
largely confined to the trunk, leg and foot, while
nmMRSA and MSSA infections were more widely
distributed and included the head and neck, although
leg and foot remained the most common infection sites.
Initial patient management did not differ by resist-
ance group, despite the differences noted in patient
profile and infection site. In this sample, any MRSA
infection was more likely to have led to multiple
follow-up visits than MSSA, but the differences in
average visits in the isolate groups were not statisti-
cally significant.
Drainage was performed in less than a third of
all cases, even though incision and drainage alone
may be the optimal treatment for skin and soft tissue
infections. On the other hand doctors reported that
they had prescribed antibiotics for nearly all infec-
tions (88%, 95% CI 80–93). Most cases were treated
with flucloxacillin, which was the common practice
in Australia at the time (71/94, 95% CI 66–84).
Figure 2 shows that the overall pattern of antibiotic
prescribing was the same across all cases, regardless
of the antibiogram of the isolate causing the infection,
indicating that these infections did not present any dif-
ferently to the treating doctor to signal the likelihood
of flucloxacillin resistance.
The isolate responsible for the infection was resist-
ant to the prescribed antibiotic 100% of the time for
mMRSA infections, 73% of the time for nmMRSA,
and 3% of the time for MSSA. Given that we have
under-sampled MSSA, the majority of doctors still
All S. aureus clinical isolates April–August 2006
general, blood, urine & respiratory benches
first screen to exclude duplicates and known
healthcare facility onset infections (>48 hours
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50 mMRSA 62 nmMRSA 64 MSSA
91% 79%94%
15 mMRSA 34 nmMRSA 57 MSSA
30% 91%55%
Fig. 1. Recruitment. mMRSA, Multiresistant methicillin-resistant S. aureus; nmMRSA, non-multiresistant MRSA;
MSSA, methicillin-sensitive S. aureus.
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prescribed microbiologically active antibiotics (esti-
mated at 92·5% adjusting for sampling fractions).
Subsequent prescription choices, and/or a decision to
incise and drain, appeared to follow patient failure
to respond to initial treatment and/or were influenced
by the antibiotic resistance details provided subse-
quently on the laboratory report following the wound
swab.
Presence of PVL encoding genes
The overall prevalence of PVL encoding genes
(lukS-PV/lukF-PV) was 22% (23/103); 42·4% of
nmMRSA (95% CI 26–61), 16% of MSSA (95% CI
8–28) and none of the MRSA (one-sided 97·5% CI
0–23). Patient and infection characteristics were
further analysed by PVL status for pooled
nmMRSA and MSSA strains (Table 2). Patients
with PVL-positive infections were more likely to
be younger with a 29-year difference in average age
(P<0·001). The distribution of infection site also var-
ied according to PVL (P=0·005), with PVL-positive
infections seen more frequently in the head, neck,
trunk and axilla, and less frequently in the leg and
foot than for PVL-negative infections.
Antibiotic prescription was the initial treatment
choice for 90% of cases in both groups, but interest-
ingly drainage was performed in 55% of infections
that were subsequently identified as PVL positive
compared to only 19% of PVL negative (P=0·005).
Hence initial management decisions appeared to be
influenced by isolates carrying PVL genes because in
Table 1. Clinical features by antibiotic resistance group
mMRSA nmMRSA MSSA Total
Patients, N 15 34 57 106
Age (years), mean (95% CI) 70·1 (63–77) 47·1 (38–57) 43·3 (37–50) 48·3 (43–53)
Range 50–88 1–93 1–86 1–93
Gender females, n (%, 95% CI) 9 (60%, 32–84) 19 (56%, 37–77) 31 (54%, 41–67) 59 (56%, 46–65)
Antibiotic use in previous
12 months, n (%, 95% CI)
9/10 (90%, 55–98) 15/23 (65%, 43–84) 22/48 (46%, 31–61) 46/81 (57%, 45–68)
Infection and treatment
Doctor-rated severity, n (%)
Mild 6 (40%) 9 (26%) 22 (39%) 37 (35%)
Moderate 7 (47%) 20 (59%) 29 (51%) 56 (53%)
Severe 2 (13%) 5 (15%) 6 (11%) 13 (12%)
Skin and soft tissue infection 14 (93%) 33 (97%) 52 (91%) 99 (93%)
Infection site, n (%)
Head and neck 0 (0%) 7 (21%) 8 (14%) 15 (14%)
Trunk 3 (20%) 1 (6%) 7 (12%) 12 (11%)
Axilla 0 (0%) 4 (12%) 1 (2%) 5 (5%)
Arm and hand 0 (0%) 4 (12%) 10 (18%) 14 (13%)
Groin and perianal 1 (7%) 1 (3%) 2 (4%) 4 (4%)
Leg and foot 9 (60%) 14 (41%) 26 (46%) 49 (46%)
Other 2 (13%) 2 (6%) 3 (5%) 7 (7%)
Antibiotics prescribed for
this infection, n (%)
11 (73%) 31 (91%) 51 (89%) 93 (88%)
95% CI 45–92 95% CI 76–98 95% CI 78–96 95% CI 80–93
Antibiotic known, and isolate
found to be resistant to prescribed
antibiotic, n (%)
9/9 (100%) 24/30 (80%) 2/47 (4%) 35/86 (41%)
95% CI 66–100* 95% CI 61–92 95% CI 0·1–15 95% CI 30–52
PVL genes present, n (%) 0/14 (0%) 14/33 (42·4%) 9/56 (16%) 23/103 (22%)
95% CI 0–23* 95% CI 26–61 95% CI 8–28 95% CI 15–32
Drainage performed, n (%) 5/14 (36%) 12/32 (38%) 12/53 (23%) 29/99 (29%)
95% CI 13–65 95% CI 21–56 95% CI 13–37 95% CI 21–39
Follow-up visits
Mean (95% CI) 3·3 (1·1–5·4) 3·4 (1·3–5·5) 1·9 (1·0–2·7) 2·5 (1·7–3·3)
Median 2·5 1·0 1·0 1·0
* One-sided 97·5% CI.
mMRSA, Multiresistant methicillin-resistant S. aureus; nmMRSA, non-multiresistant MRSA; MSSA, methicillin-sensitive
S. aureus; CI, confidence interval; PVL, Panton–Valentine leukocidin.
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this study PVL isolates often presented as boils or
abscesses.
Multivariate analysis was used to model PVL as
a predictor of drainage being performed, adjusted
for infection type, site and patient’s age (Table 3).
Most factors that were significantly associated with a
decision to incise and drain in univariate analyses
became non-significant in the multivariate model
(PVL, infection site, type, patient’s age). However,
the presence of PVL-encoding genes remained
strongly associated with a decision to lance and
drain, with patients 4·8 times more likely to have an
infection caused by a PVL-positive isolate (95% CI
1·5–15·2) if the doctor performed drainage, indepen-
dent of infection type, site or patient’s age.
MRSA prevalence in community-onset infections
In order to estimate the proportion of community-
onset infections caused by MRSA, the eligibility
fractions for community onset that were determined
in this study (Fig. 1) were applied to the total num-
ber of isolates believed to be associated with individ-
ual infection episodes. We estimated that over this
5-month period 3·5% (95% CI 2·2–4·9) of a total of
2094 infections referred to this community-based
laboratory were due to MRSA.
Clonal diversity
The PFGE pattern for all 14 mMRSA characterized
was equivalent to ST239-MRSA-III, the dominant
healthcare-associated MRSA clone isolated in Mel-
bourne hospitals [21]. All were PVL negative (see
Table 4).
The 33 nmMRSA consisted of 13 clones: two
healthcare-associated MRSA (HA-MRSA) and 11
community-associated MRSA (CA-MRSA). The two
HA-MRSA clones, EMRSA-15 (three isolates) and
EMRSA-16 (one isolate), were PVL negative. The
CA-MRSA clones included three international
PVL-positive clones; USA300 (one isolate), Taiwan
CA-MRSA (one isolate) and South West Pacific
(SWP CA-MRSA) (two isolates). The remaining eight
CA-MRSA clones included the five dominant
CA-MRSA clones isolated in Australia [11]; PVL-
positive Queensland (Qld) CA-MRSA (ST93-
MRSA-IV), WA1 CA-MRSA (ST1-MRSA-IV), of
which two isolates were PVL positive, WA23 CA-
MRSA (ST45-MRSA-IV), WA2 CA-MRSA (ST78-
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Single isolates of WA5 CA-MRSA (ST8-MRSA-IV),
PVL-positive WA15 (ST59- MRSA-IV) and a novel
CA-MRSA, PVL-positive ST5-MRSA-IV were also
characterized. Overall, the nmMRSA population con-
sisted of eight CCs and one singleton.
The MSSA population consisted of 25 different
PFGE pulsotypes. The PVL determinants were
found in eight different lineages, consisting of at
least four clonal clusters and one singleton (ST1, ST
DLV, ST20, ST30, ST93, ST121, ST152, ST772).
Three of the PVL-positive lineages (ST1, ST30,
ST93) were also identified in the nmMRSA popu-
lation (WA1 CA-MRSA, SWP CA-MRSA, Qld
CA-MRSA).
DISCUSSION
The aim of the study was to obtain an epidemiological
snapshot of S. aureus infections in the community
without making a priori assumptions about disease
severity, resistance or virulence. This approach has
enabled us to examine infections that are not captured
Table 2. Clinical features by PVL status for nmMRSA and MSSA infections (n=89)
PVL negative PVL positive P value*
Study patients, N 66 23
Age (years) <0·001
Mean (95% CI) 52 (46–58) 23 (16–31)
Range 1–93 1–68
Gender,% female (95% CI) 55% (42–67) 57% (34–77) 0·870
Infection severity, n (%, 95% CI) 0·677
Mild 23 (35%, 24–48) 8 (35%, 16–57)
Moderate 36 (55%, 42–67) 11 (48%, 27–69)
Severe 7 (11%, 4–21) 4 (17%, 5–39)
Infection site, n (%) 0·005
Head and neck 10 (15·2%) 5 (21·7%)
Trunk 6 (9·1%) 3 (13·0%)
Axilla 0 (0·0%) 5 (21·7%)
Arm and hand 9 (13·6%) 3 (13·0%)
Groin and perianal 3 (4·5%) 0 (0·0%)
Leg and foot 34 (51·5%) 6 (16·1%)
Other 4 (6·1%) 1 (4·3%)
Antibiotics prescribed, n (%, 95% CI) 59/66 (89%, 79–96) 21/23 (91%, 72–99) 0·939
Drainage performed, n (%, 95% CI) 12 (19%, 11–32) 12 (55%, 32–76) 0·002
Boils or abscess, n (%, 95% CI) 13 (20%, 7–25) 14 (61%, 36–79) <0·001
Follow-up
Mean number visits (95% CI) 2·7 (1·5–3·9) 1·7 (0·8–2·5) 0·315
Mean duration days (95% CI) 16·4 (12–21) 11 (6–16) 0·184
Antibiotics in previous 12 months 30/57 (52·6%) 6/16 (37·5%) 0·285
PVL, Panton–Valentine leukocidin; nmMRSA, non-multiresistant methicillin-resistant S. aureus; MSSA, methicillin-sensitive
S. aureus; CI, confidence interval.
Table 3. Logistic regression model for drainage treatment (n=76)
Crude OR (95% CI) P value Adjusted OR (95% CI) P value
PVL 4·9 (1·7–14·0) 0·002 4·8 (1·5–15·2) 0·008
Age (by year) 0·98 (0·97–0·99) 0·000 1·00 (0·96–1·01) 0·792
Boil/abscess 2·95 (1·04–8·35) 0·038 1·21 (0·31–4·7) 0·787
Infection site
Other Reference Reference
Head and neck 6·0 (0·5–67·6) 0·147 3·8 (0·32–46) 0·290
Axilla 14·8 (1·5–143·7) 0·020 1·7 (0·13–24) 0·680
OR, Odds ratio; CI, confidence interval; PVL, Panton–Valentine leukocidin.
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through hospital admissions alone, and to understand
the way these infections present and are managed
in the community. In this study of community-based
staphylococcal infections, the treating clinicians,
mainly general practitioners, were asked to rate sever-
ity, report their initial and subsequent treatment
decisions and describe the type and location of the
infections they were managing. By including all
patients with MRSA infection and a random sample
of MSSA infections, we were able to create and com-
pare three comparative groups with community-onset
mMRSA, nmMRSA or MSSA infections.
We compared clinical presentation and manage-
ment of nmMRSA and MSSA case-patients by the
PVL status of their isolate. At the time of presen-
tation, clinicians have to make treatment decisions
Table 4. Molecular characterization of S. aureus isolates
PFGE MLST/SCCmec CC Number PVL positive (n)
mMRSA (14) Aus2/3 ST239-MRSA-III* 8 14 0
nmMRSA (33) WA1 ST1-MRSA-IV* 1 6 2
WA2 ST78-MRSAIV* 78 3 0
WA3 ST5-MRSA-IV* 5 3 0
WA5 ST8-MRSA-IV* 8 1 0
Taiwan ST59-MRSA-VT 59 1 1
WA15 ST59-MRSA-IV 59 1 1
WA23 ST45-MRSA-IV 45 4 0
Qld ST93-MRSA-IV* S 6 6
SWP ST30-MRSA-IV* 30 2 2
USA300 ST8-MRSA-IV* 8 1 1
novel ST5-MRSA-IV 5 1 1
EMRSA15 ST22-MRSA-IV* 22 3 0
EMRSA16 ST36-MRSA-II* 30 1 0
MSSA (55) MSSA-1 6 0








ST1 DLV 1 1
MSSA-10 5 0





MSSA-16 ST20 20 1 1
MSSA-17 4 0
MSSA-18 ST772 1 1 1
MSSA-19 ST152 ND 1 1
MSSA-20 1 0






PFGE, Pulsed-field gel electrophoresis; MLST, multilocus sequence type; SCCmec, staphylococcal cassette chromosome mec;
CC, clonal complex; PVL, Panton–Valentine leukocidin; mMRSA, multiresistant methicillin-resistant S. aureus; nmMRSA,
non-multiresistant MRSA; MSSA, methicillin-sensitive S. aureus; ST, sequence type; DLV, double locus variant.
*MLST inferred from PFGE pattern.
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without knowledge of the resistance profile, although
this is generally available within 48–72 h. PVL status
was not available to any of the clinicians during the
study as it was only determined later for research pur-
poses. The strength of this study therefore is that any
differences in clinical presentation and initial manage-
ment were likely to be linked to intrinsic resistance
and/or virulence of the responsible strains, and not
influenced by practitioner preconceptions about the
significance of MRSA or PVL.
The majority of our patients with S. aureus infec-
tions in all groups presented with skin and soft tissue
infections, and in this regard our results are comp-
lementary to hospital-based studies which often
focus on bacteraemia [5, 6, 24–27]. Our principal
finding was that CA-MRSA infections were still rela-
tively uncommon in suburban Melbourne in late 2006,
contributing an estimated 3·5% (95% CI 2·2–9·5) of
all community-onset S. aureus infections, and were
caused by multiple different clones. Moreover, when
they did occur, the treating clinicians did not perceive
increased severity. However, when nmMRSA and
MSSA cases were combined and analysed by PVL
status, it was clear that clinicians recognized some-
thing about these infections that led them to initiate
incision and drainage procedures more frequently
than for PVL-negative infections. This was also
recently reported in hospital-based studies in New
Zealand and Spain [28, 29]. In our study this associ-
ation persisted even when we controlled for the pres-
ence of boils, age and infection site.
Some reports have suggested that PVL is a stable
marker of the presence of methicillin resistance in
community-onset infections [10], but in contrast we
found that 58% of nmMRSA isolates were PVL nega-
tive and that 15% of our MSSA isolates were PVL
positive. Furthermore, it was the presence of PVL
that correlated with a perceived need to undertake
incision and drainage, not the detection of MRSA
per se, as also reported in studies from Spain, New
Zealand, Sweden and France [27, 29–32].
There is an emerging view that the biological role
of PVL may be to allow direct invasion of human
skin so that CA-MRSA may disseminate via clinically
active skin infection rather than relying solely on
asymptomatic colonization of mucus membranes
[33–37]. In support of this view are reports that PVL
is less likely to be present in blood culture isolates
than isolates obtained from aggressive skin infections
or necrotizing pneumonia [26, 29]. Our data would
fit this model but suggest that the presence of PVL
is responsible for this independently of the methicillin
resistance-encoding mecA gene. Whether PVL itself is
directly responsible or is a marker of other virulence
determinants with similar properties is still not
completely determined [15], although the majority
view now is that PVL is a principal virulence determi-
nant [14].
We also observed that PVL positive infections were
more likely to occur in young people than non-PVL
infections and more likely to involve the upper
body, particularly the axilla or head and neck. The
association between PVL and young age has also
been noted by other investigators [29, 31, 37].
Possible explanations include age-related acquisition
of PVL-specific immunity. However, a recent study
has reported that children acquire neutralizing anti-
body to PVL in an age-specific fashion reaching
adult levels by the age of 3–5 years, but anti-PVL
did not appear to protect against skin and soft tissue
infections with PVL-expressing S. aureus [38].
Other explanations such as specific behaviours that
increase contact between individuals carrying
virulent clones may offer an alternative explanation
for the age-specific incidence and site of infection
location [33].
The limitations of our study include the relatively
small numbers of case-patients, the reliance on detec-
tion of PVL genes rather than gene expression in our
isolates, the possible presence of other virulence fac-
tors linked to PVL that we have not yet assessed,
and our inability to follow-up all patients; however,
our response rate was high (87%). The fact that the
patterns of initial antibiotic treatment are consistent
across the three antibiotic resistance groups in these
community-onset infections suggests that doctors are
not seeing these patients differently, and therefore
there are unlikely to be patient or infection character-
istics apparent to a treating physician that could
reliably predict whether a community-onset infection
is caused by a MRSA strain.
The cross-sectional nature of the data also limited
our ability to investigate the timing of treatment
decisions in relation to the laboratory test results
being made available to the doctor. While initial treat-
ment decisions were not influenced by knowledge of
the resistance phenotype, subsequent management
decisions would have been influenced by knowledge
of the resistance profile. However, this would not
have applied to PVL status where the results were
not determined until some time later and were not
reported to the treating doctor.
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As we identified patients with community-onset
infections via laboratory test requests, it is also possible
we over-selected for doctors who swab skin infections
and/or prescribe antibiotics. Caution must therefore
be exercised in extrapolating the prevalence of anti-
biotic prescription and drainage to the wider medical
community managing community-onset infections.
To address the issue of sample size and the limitations
of cross-sectional analyses, a larger more comprehen-
sive longitudinal study is currently underway based on
the same community-based recruitment strategy.
Our study has shown that observational studies that
avoid a priori assumptions about the S. aureus isolates
on which they are based can provide a more complete
picture of the relative incidence and importance of
resistance and virulence in this ubiquitous human
pathogen. Despite the undeniable importance of emer-
ging resistance and virulence, most staphylococcal
infections are milder than is apparent if only reports
from hospital-based studies are considered. We esti-
mate that 80% of S. aureus causing clinically signifi-
cant infections in this Melbourne-based study were
both methicillin sensitive and PVL negative, and
that appropriately active antibiotics were prescribed
in 92·5% of cases using clinical judgement and existing
protocols.
CONCLUSION
We report high levels of clonal diversity and PVL
positivity in nmMRSA and MSSA isolates respons-
ible for community-onset infections. Infections with
PVL-positive S. aureus were more common in
younger patients and presented more often as axillary,
head or neck infections. Treating doctors seem to
detect something different in the presentation of
PVL-positive infections and surgically lanced and
drained these infections more frequently. The associ-
ation between PVL and drainage is independent of
the age of patient and type and site of the skin infec-
tion. While we did not find doctor-rated infection
severity to be associated with PVL positivity, the
observed increase in frequency of drainage procedures
performed in PVL-positive infections is suggestive of a
relationship between PVL positivity and the ability to
form a drainable collection.
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